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(OAD) adherence-enhancing interventions and to explore which of the
behavior change techniques (BCTs) applied in the intervention groups
modiﬁed this pooled intervention effect size. Methods: We searched
relevant studies published until September 3, 2013, on MEDLINE,
Embase, PsycInfo, the Cochrane Library, CINAHL, Current Contents
Connect, and Web of Science. Selected studies were qualitatively
synthesized, and those of at least medium quality were included in
the meta-analysis. A random-effects model was used to pool effec-
tiveness (Hedges’s g) and to examine heterogeneity (Higgins I2). We
also explored the inﬂuence on the pooled effectiveness of unique
intervention BCTs (those delivered to the intervention groups but not
control groups in a trial) by estimating their modifying effects.
Results: Fourteen studies were selected for the qualitative synthesis
and 10 were included in the meta-analysis. The pooled effectiveness
of the interventions was 0.21 (95% conﬁdence interval 0.05 to 0.47;ee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.02.017
ette@pha.ulaval.ca.
ndence to: Line Guénette, CHU de Quebec Researc
1S 4L8.I2 ¼ 82%). Eight unique BCTs were analyzed. “Cope with side effects”
(P ¼ 0.003) and “general intention formation” (P ¼ 0.006) had a
modifying effect on the pooled effectiveness. The pooled effectiveness
of the interventions in which “cope with side effects” was applied was
moderate (0.64; 95% conﬁdence interval 0.31–0.96; I2 ¼ 56%). Conclu-
sions: The overall effectiveness of OAD adherence-enhancing inter-
ventions that have been tested is small. Helping patients cope with side
effects or formulate desired treatment outcomes could have an impact
on the effectiveness of OAD adherence-enhancing interventions. Only
those interventions that include helping patients to cope with side
effects appear to be particularly effective in improving OAD adherence.
Keywords: adherence, diabetes, oral antidiabetic drug, meta-analysis,
intervention.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In 2011, approximately 366 million people worldwide suffered
from diabetes, and this number could reach 552 million by 2030
[1,2]. In 2011, the global diabetes burden was estimated to be at
least US $465 billion, and this represented 11% of adult health
care costs worldwide [2]. A large proportion of this burden is
attributed to type 2 diabetes, which accounts for more than 90%
of all diabetes cases [3].
To prevent microvascular (retinopathy, nephropathy, and
neuropathy) and macrovascular (cardiovascular and cerebrovas-
cular diseases and leg amputations) diabetes complications,
patients with type 2 diabetes should achieve certain target blood
glucose levels (typically, glycated hemoglobin level of o7%)
through regular physical activity, a healthy diet with low carbo-
hydrate intake, and appropriate use of drug treatment [4]. Oralantidiabetic drugs (OADs), when taken as recommended, can
substantially contribute to achieving metabolic control [5,6],
which thereby improves quality of life [5]. Even though insulin
can be used alone or in combination with OADs, nearly 60% of the
individuals with type 2 diabetes use only OADs to control their
diabetes [7]. Unfortunately, patient adherence to OAD treatment
is often poor [8,9], which contributes to suboptimal metabolic
control [10,11], increased diabetes complications and hospital-
izations [12,13], and increased health care expenditures [14].
Adherence to OAD treatment could be optimized by exposing
patients to effective behavior change interventions. Two system-
atic reviews [15,16] have been previously conducted, but these
focused on only OAD adherence-enhancing interventions deliv-
ered by pharmacists and did not assess the overall effectiveness
of the interventions. In addition, recent advances in the coding of
published behavior change interventions have made it possible toociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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components [17]. Moreover, there is growing evidence that not
only intervention groups but also control groups in adherence-
enhancing interventions are exposed to effective behavioral
support (e.g., as part of usual care) that can vary between studies
and have an impact on intervention effects. Hence, we performed
a systematic review and a meta-analysis of the effectiveness of
interventions aimed at enhancing OAD adherence in adults with
type 2 diabetes. The aim was to identify the behavior change
techniques (BCTs) delivered to both the intervention and the
control groups, estimate the pooled intervention effect size, and
explore which of the BCTs that were applied in the intervention
groups (but not the control groups) modiﬁed this pooled
effect size.Methods
The present study was performed according to the guidelines of
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses [18,19].
Literature Search
We conducted a literature search of studies using MEDLINE (via
PubMed), Embase, PsychInfo, the Cochrane Library, CINAHL PLUS
with Full Text, Current Contents Connect (Social & Behavioral
Sciences [from 1998 to present], Clinical Medicine [from 1998 to
present], Engineering, Computing & Technology [from 1998 to
present]), and Web of Science. We searched databases from their
start dates through September 3, 2013 (see search strategies in
Appendix Table S1 in Supplemental Materials found at 10.1016/j.14,450 articles identified through 
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Fig. 1 – Flow chart of article selection in thejval.2015.02.017 and the results in Fig. 1). Search results were
downloaded and imported directly into EndNote, version X4 [20].
No language restriction was applied. An information scientist (F.
B.) assisted us in developing an optimal search strategy.
Eligibility Criteria and Study Selection
We deﬁned eligibility criteria on the basis of PICOS (participants,
intervention, comparator, outcomes, and study design) [18].
Types of Participants
All studies that focused on adults 18 years or older with type 2
diabetes who used OADs.
Types of Interventions
Interventions with at least one component aimed at improving
OAD adherence, regardless of the methods or techniques used.
Comparator
Individuals with type 2 diabetes who were exposed to usual care
and/or to an intervention of any sort.
Outcomes
The main outcome was OAD adherence. We included original
studies in which OAD adherence was measured both before and
after the intervention.
Study Designs
We included randomized controlled trials, quasi-experimental
studies, and controlled pre-/posttest studies.2 additional articles after the update of 
database searching; 0 articles identified 
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systematic review and meta-analysis.
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and N.P.) screened the titles, abstracts, and full texts of the
remaining articles. The coders also manually searched the biblio-
graphic reference lists of eligible articles and previous systematic
reviews. If the results of a study were reported in more than one
publication, we retained only the publication with the most
complete results. We included publications on the same study
only if they focused on different populations.
Data Extraction
A data collection form based on the data collection guide of the
Cochrane Collaboration was developed (see details in Appendix
Table S2 in Supplemental Materials found at 10.1016/j.jval.2015.
02.017). Two coders independently extracted data from the
selected studies. Disagreements were resolved by consensus after
discussion or, if necessary, by a third author. To obtain missing
information on the primary outcome or to clarify information,
corresponding authors were contacted by e-mail. All correspond-
ing authors of the selected studies were also asked to send us
their intervention protocols, manuals, or any documents that
described the interventions offered to the control and interven-
tion groups. Descriptions of usual care/standard care compo-
nents were not requested for multisite studies because this
information was assumed to be unavailable to the study authors.
If there was no reply after 2 weeks, a reminder e-mail was sent.
Study Details
Two authors (H.T.V.Z and N.P.) extracted the following informa-
tion: general information such as ﬁrst author’s names and year of
publication, population and setting, methods, participants, inter-
vention groups, outcomes, results, and the main conclusions of
the study authors.
Categorization of Intervention Components
The ﬁrst author (H.T.V.Z.) prepared the available documents and
corresponding articles for coding by concealing the names of the
study authors, the journals of publication, the results, the discus-
sions, and the conclusions. To identify the BCTs used in the selected
studies, two coders (L.A.V. and La.G.) independently categorized the
components of the interventions in both the intervention and
control groups using the coding manual for BCTs in adherence
interventions (see Appendix Table S3 in Supplemental Materials
found at 10.1016/j.jval.2015.02.017), adapted to diabetes care with the
support of the original author (M.d.B.) [21,22]. Disagreements in
codiﬁcation were resolved by consensus between the two coders.
Assessment of Internal (Risk of Bias) and External validities
H.T.V.Z. and N.P. independently assessed the internal (risk of
bias) and external validity of the selected studies using a
checklist based on the Methods for the Development of NICE
Public Health Guidance [23]. The checklist has ﬁve sections (see
Appendix Table S2, item 10), namely, population, allocation,
outcomes, analyses, and external and internal validity summary.
The items are rated as good, medium, low, not reported, or not
applicable. The coders also rated overall study quality by grading
internal and external validities as good, medium, or low.
Data Synthesis and Analysis
All selected studies were described in detail with regard to each
study and each OAD adherence measure as well as intervention
and control group characteristics.
Because there were between-study differences in the instru-
ments used to measure OAD adherence, we estimated the
individual intervention effect sizes on OAD adherence using
Hedges’s g (bias-corrected standardized mean difference [SMD])and a 95% conﬁdence interval (CI) [24]. When there was more
than one type of OAD adherence measure, only the one for which
there were both pre- and postintervention values or the one used
in most of the studies was included. When there was more than
one postintervention measure, we considered the one that was
nearest the end of the intervention.
When adherence was reported on a continuous scale, we
directly computed Hedges’s g on the basis of sample sizes and
adherence means of both intervention and control groups. To be
able to pool studies in which OAD adherence was reported as a
binary variable with those in which it was reported as a
continuous variable, we made the following transformation for
OAD adherence binary variables. We calculated the odds ratio,
converted it to Cohen’s d using the formula d ¼ 31/2 ln(odds ratio)/
π [24,25], which was then transformed into SMD (Hedges’s g) ¼
[(1–3/(4N1 þ 4N2 – 9))  d], with N1 being the intervention group
sample size and N2 being the control group sample size [24]. Our
review focused on a wide variety of behavioral interventions
aiming to enhance OAD adherence. Therefore, we anticipated
that there would be heterogeneity in the estimate of the pooled
intervention effect size. To take into account this potential
heterogeneity, a random-effects model was used to estimate
the pooled intervention effect size and its 95% CI [26]. Pooled
SMD values of less than 0.2, 0.2 or more to less than 0.5, 0.5 or
more to less than 0.8, or 0.8 or more were considered very small,
small, medium, and large, respectively [27].
Potential heterogeneity was tested by using the chi-square
test and quantiﬁed with the Higgins I2 statistic [28,29]. We used a
forest plot to analyze the pooled intervention effect size on OAD
adherence. We also performed multiple sensitivity analyses,
namely, analyzing the inﬂuence of individual studies on hetero-
geneity by removing each study one by one in the estimation of
the pooled SMD. Only studies with at least medium internal
validity were included in the meta-analysis [18].
We analyzed the inﬂuence of BCTs on the pooled intervention
effect size by comparing the pooled intervention SMD containing
a given BCT with the pooled SMD of those in which that BCT was
not applied. For these analyses, we considered only those BCTs
that were applied in intervention groups (i.e., not in control
groups) in a given trial. Because multiple comparison tests were
done, we used the Bonferroni method to correct the observed P
value from the signiﬁcance tests by multiplying this P value by
the number of tests [30].
Subgroup analyses were conducted when possible, that is, for
subgroups of at least three studies. We assessed the potential
publication bias with funnel plot and nonparametric “trim and
ﬁll” methods [31] using Macro PubBias SAS [32]. Analyses were
conducted using RevMan (version 5.2) [33] and SAS (version 9.3)
[34] software.Results
Study Selection and Study Characteristics
Out of 7561 studies reviewed, 14 were selected to be included in
the qualitative analysis. Agreement between reviewers was sub-
stantial [35] for title and abstract screening (κ ¼ 0.65) and for full-
text selection (κ ¼ 0.72). The study selection process is described
in Figure 1.
Participants’ sociodemographic characteristics at baseline and
at follow-up are summarized in Table 1. The studies were
published between 2004 and 2013, with ﬁve studies published
in 2012 [36–40]. Most of the studies were conducted in the United
States [36,38,39,41–46]. All studies but one [42] were randomized
controlled trials, and were conducted in diverse settings. Sample
sizes ranged from 33 to 526 participants, except for the study by
Table 1 – Sample, participant characteristics, and follow-up.
Study Sample Participant characteristics at baseline Participant
follow-up
1. Authors
2. Year
3. Design
1. Sample size
2. Intervention/control
3. Setting/country
1. Age (y), mean  SD
2. Sex: men, n (%)
3. Race (%): white; black; other
4. Low income
5. Diabetes duration
6. Hb A1c rate (%), mean  SD
7. OAD adherence mean
1. Duration
2. Number at the end
(I/ C)
3. Retention rate (I/C)
1. Rothschild et al. [45]
2. 2014
3. RCT
1. 144
2. 73/71
3. Homes þ medical center/USA
1. 53.7  12.2
2. 47 (32.6)
3. 0; 0; 100
4. Yes
5. NR
6. 8.3  2.0
7. 37% nonadherents
1. 24 mo
2. 119 (58/61)
3. 82.6% (7.5%/85.9%)
1. Zolfaghari et al. [40]
2. 2012
3. RCT
1. 80
2. 39/41
3. Iranian Diabetes Association/Iran
1. 52.4  NR
2. 36 (46.8)
3. NR
4. Yes (majority)
5. 8.0 y
6. 9.2  NR
7. 75%; 0 (low) to 100 (high)
1. 6 mo
2. 77 (38/39)
3. 96.3% (97.4%/95.1%)
1. Odegard and Christensen [39]
2. 2012
3. RCT
1. 265
2. 120/145
3. Pharmacies/USA
1. 62.8  NR
2. 127 (48.1)
3. NR
4. NR
5. NR
6. Not assessed
7. 85%; 0 (low) to 100 (high)
1. 12 mo
2. 255 (118/137)
3. 96.2% (98.3%/94.5%)
1. Lin et al. [38]*
2. 2012
3. RCT
1. 214
2. 106/108
3. Primary care clinics/USA
1. 56.8  11.3
2. 86 (47.6)
3. NR
4. NR
5. NR
6. 8.0  NR
7. 83%; 0 (low) to 100 (high)
1. 12 mo
2. 181 (91/90)
3. 84.6% (85.8%/83.3%)
1. Farmer et al. [37]
2. 2012
3. RCT
1. 211
2. 126/85
3. General practices/UK
1. 63.2  10.7
2. 138 (65.4)
3. NR
4. NR
5. 6.8 y
6. 8.3  1.2
7. 23.6; 5 (low) to 25 (high)
1. 5 mo
2. 195 (114/81)
3. 92.4% (90.5%/95.3%)
1. Brennan et al. [42]†
2. 2012
3. NRCT
1. 29,247
2. 5,123/24,124
3. Pharmacies/USA
1. 63.1  NR
2. 16,586 (56.7)
3. NR
4. No
5. NR
6. Not assessed
7. Graph form
1. 18 mo
2. NR
3. NR
1. Bogner et al. [36]
2. 2012
3. RCT
1. 182
2. 94/88
3. Primary care practices/USA
1. 57.5  NR
2. 58 (32.2)
3. 36.1; 56.7; 7.2
4. NR
5. 11 y
6. 7.2  NR
7. 60% nonadherents
1. 3 mo
2. 180 (92/88)
3. 98.9% (97.8%/100%)
1. Walker et al. [46]*
2. 2011
3. RCT
1. 526
2. 262/264
3. Worker union fund/USA
1. 55.5
2. 173 (32.9)
3. 5.9; 61.6; 32.5
4. Yes (majority)
5. 9.2 y
6. 8.6 (median)
7. Measured but NR
1. 12 mo
2. 444 (228/216)
3. 84.4% (87.0%/81.8%)
1. Mehuys et al. [48]†
2. 2011
3. RCT
1. 66 pharmacies (288 patients)
2. 35 (153)/31 (135)
3. Pharmacies/Belgium
1. 62.7  NR
2. 151 (52.3)
3. NR
4. NR
5. NR
6. 7.5  NR
7. 38.1% (nonadherents, at least
1 time/y)
1. 6 mo
2. 280 (148/132)
3. 97.2% (96.7%/97.8%)
1. Nesari et al. [47]
2. 2010
3. RCT
1. 61
2. 30/31
3. Iranian Diabetes Association/Iran
1. 51.5
2. 17 (28.3)
3. NR
4. Yes (majority)
5. Z2 y (81.7%)
6. 8.9  NR
7. 61%; 0 (low) to 100 (high)
1. 12 mo
2. 60 (30/30)
3. 98.4% (100%/96.8%)
1. Heisler et al. [43]
2. 2010
3. RCT
1. 244
2. 125/119
3. Veterans clinics/USA
1. 62.0  6.3
2. 244 (100)
3. 82; 9; 9
4. Yes (majority)
5. NR
6. 8.0  1.4
7. 69% nonadherents
1. 6 mo
2. 231 (117/114)
3. 94.7% (93.6%/95.8%)
1. Bogner et al. [41]
2. 2010
3. RCT
1. 58
2. 29/29
3. Primary care practice/USA
1. 60.0  NR
2. 9 (15.5)
3. 0; 100; 0
4. NR
5. NR
6. 7.3
7. 66% nonadherents
1. 3 mo
2. 58 (29/29)
3. 100% (100%/100%)
1. Phumipamorn et al. [49]†
2. 2008
3. RCT
1. 135
2. 67/68
3. Community hospital/Thailand
1. 54.1  NR
2. 21 (16.2)
3. NR
4. NR
5. 6.4 y (NR)
6. 8.7  1.5
7. 85%; 0 (low) to100 (high)
1. 6 mo
2. 130 (63/67)
3. 96.3% (94.0%/98.5%)
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Participants’ mean ages varied from 51.5 to 63.2 years. At base-
line, hemoglobin A1c mean rates varied from 7.2% to 9.2% and
participants’ average OAD adherence levels were suboptimal in
six studies [36,40,41,43,44,47]. Study follow-up periods ranged
from 3 to 24 months (median ¼ 6.5 months), and study retention
rates ranged from 82.6% to 100%.
Assessment of Internal (Risk of Bias) and External Validities
The internal and external validities of the included studies are
presented in Appendix Table S4 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2015.02.017 Internal validity was
good in four studies [43,45–47], medium in seven studies [36–
41,44], and low in three studies [42,48,49]. Hence, 11 studies had
medium to high internal validity and were eligible for meta-
analysis. External validity was medium in 4 studies [36,37,39,46]
and low in the other 10 studies [38,40–45,47–49].
OAD Adherence Measure Characteristics
The characteristics of OAD adherence measures are described in
Appendix Table S5 in Supplemental Materials found at 10.1016/j.
jval.2015.02.017. OAD adherence was the primary outcome in
eight studies [36–41,44,47]. It was self-reported in seven studies
[37,40,43–47] and was measured with medication event monitor-
ing systems in ﬁve studies [36,37,41,44,45] and with prescription
claims data in three studies [38,39,46]. Two instruments (medi-
cation event monitoring systems or prescription claims data plus
self-report) were used in three studies [37,44,46].
Intervention Characteristics
The intervention characteristics are summarized in Table 2. Only
one intervention [37] was guided by theory, and this intervention
used the theory of planned behavior [50]. The intervention imple-
mentation periods ranged from 1 day to 24 months. The planned
number of sessions with patients ranged from 1 to 72. Intervention
delivery mode was dual in seven studies [36,38,39,41,43,44,46], with
phone calls being the most-used mode [36,38,39,41,43,46] in addi-
tion to face-to-face meetings [36,38,39,41], group meetings [43], and
mail [46]. An intervention guide or a manual was used by those who
conducted the intervention in seven studies [36,37,39,41,43,45,46].
The authors report having assessed intervention ﬁdelity, that is,
how the interventionists complied with the intervention guide or
manual, in only two studies [39,45]. The interventionists were
trained and coached during intervention implementation in seven
studies [36,37,39,41,43,45,46]. Interventions were conducted by the
researchers in four studies [36,40,41,44] and by nurses in three
studies [37,38,47]. In the remaining four studies, nurses and patients
(peer support) [43], community health workers [45], pharmacists
[39], or health educators [46] conducted the interventions.
Components of the Interventions in the Control and
Intervention Groups
Table 2 presents the components of the interventions offered to
the control and intervention groups. Interventions offered to
control groups, especially usual care, could not be categorized
in 5 of the 11 studies [36–39,41], but all interventions (11 studies)
in the intervention groups were categorized. In total, 25 BCTs
were categorized in the intervention and control groups, and 22
of these were applied in only the intervention groups for a given
trial. Eight of these 22 BCTs were offered in three or more studies:
“provide general information” [36–39,41], “plan coping responses”
[38,39,46,47], “self-report of behavior” [36,38,41], “reinforce moti-
vational progress” [37,38,41], “speciﬁc goal setting” [37–39,46],
“continuous professional support” [38,39,45], “general intention
Table 2 – Characteristics and components of interventions in the 10 studies retained for meta-analysis.
Study Intervention characteristics Components of interventions Interventionist
1. Authors
2. Year
3. RCT
1. Psychosocial
theory
2. Intervention
period
3. Number of
sessions
4. Delivery
mode used
5. Guide used
6. Intervention
ﬁdelity
1. Intervention group 2. Control group 1. Proﬁle
2. Training
3. Coaching
1. Rothschild
et al. [45]
2. 2014
3. RCT
1. Not used
2. 24 mo
3. 36
4. Face to face
5. Yes
6. Assessed
EMB; provide general information; plan coping responses;
general intention formation*; self-monitoring of
behavior; REB; use of social support; practice, guided
practice*; feedback: delayed feedback of behavior*;
continuous professional support*
EMB; provide general information; plan coping
responses; use of social support; self-
monitoring of behavior; REB
1. CHW
2. Yes
3. Yes
1. Zolfaghari
et al. [40]
2. 2012
3. RCT
1. Not used
2. 3 mo
3. 72
4. SMS
5. No
6. Not assessed
Provide general information; plan coping responses Provide general information; risk
communication†; self-monitoring of
behavior†; self-report of behavior†; plan
coping responses
1. Researcher
2. No
3. No
1. Odegard and
Christensen
[39]‡
2. 2012
3. RCT
1. Not used
2. 12 mo
3. 3.4
4. Face to face þ
phone calls
5. Yes
6. Assessed
Plan coping responses*; provide general information*;
speciﬁc goal setting*; continuous professional support*;
EMB; persuasive argument, belief selection*; cope with
side effects*
EMB; usual care (cannot be coded) 1. Pharmacists
2. Yes
3. Yes
1. Lin et al. [38]‡
2. 2012
3. RCT
1. Not used
2. 12 mo
3. 24–36
4. Face to face
þ phone calls
5. No
6. Not assessed
Speciﬁc goal setting*; reinforcement on motivational
progress*; provide general information*; plan coping
responses*; formulate goals for maintenance of
behavior*; relapse prevention*; continuous professional
support*; general intention formation*; reﬂective
listening*; reevaluation of outcomes*; self-report of
behavior*; individualize regimen*
Cannot be coded 1. Nurse
2. No
3. No
1. Farmer et al.
[37]‡
2. 2012
3. RCT
1. Theory of
planned
behavior
2. 1 d
3. 1
4. In person
5. Yes
6. Not assessed
Persuasive argument*; mobilize social norms*; plan coping
responses; reinforcement on motivational progress*;
provide general information*; speciﬁc goal setting*; use of
cues*; EMB; self-report of behavior; general intention
formation*
EMB; self-report of behavior; usual care
(cannot be coded)
1. Nurses
2. Yes
3. Yes
1. Bogner et al.
[36]‡
2. 2012
3. RCT
1. Not used
2. 3 mo
3. 5
4. Face to face þ
phone calls
5. Yes
6. Not assessed
Provide general information*; cope with side effects*; use of
cues*; use of social support*; EMB; self-report of behavior*
EMB; usual care (cannot be coded) 1. Researchers
2. Yes
3. Yes
1. Walker et al.
[46]
2. 2011
3. RCT
1. Not used
2. 12 mo
3. 10
4. Phone calls
þ mail
5. Yes
6. Not assessed
Provide general information; plan coping responses*;
speciﬁc goal setting*; self-report of behavior
Provide general information; self-report of
behavior
1. Health
educators
2. Yes
3. Yes
1. Nesari et al.
[47]
2. 2010
1. Not used
2. 3 mo
3. 16
4. Phone calls
5. No
6. Not assessed
Provide general information; provide opportunities for
social comparison; individualized regimen*; plan coping
responses*
Provide general information; provide
opportunities for social comparison
1. Nurses
2. NR
3. NR
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 3 0 – 5 4 0536formation” [37,38,45], and “cope with side effects” [36,39,41]. Not
taking into account “usual care,” the total numbers of BCTs
offered in intervention groups ranged from 2 to 11 (median ¼ 7)
and from 0 to 6 (median ¼ 2) in control groups.
Pooled Intervention Effect Size on OAD Adherence
Intervention effects on OAD adherence were both positive and
statistically signiﬁcant (P o 0.05) in six studies [36,39,41,44,46,47],
null in four studies [37,38,43,45], and negative in one study [40]. A
total of 10 studies were included in the meta-analysis because
the intervention effect size could not be calculated for one study
[44]. Adherence was measured either on a dichotomous scale
[36,41,43,45,46] or a continuous scale [37,38,39,40,47]. When the
reported adherence measure was dichotomous, we used the
categorization cutoff value as reported in the study articles. In
each of the 10 study articles, there was only one intervention for
which it was possible to estimate the effect size on OAD
adherence. We pooled the effect sizes of these 10 behavioral
interventions in our meta-analysis. Because the heterogeneity
was high (I2 ¼ 82%; P o 0.001), we reported the results of only the
random-effects model (see Fig. 2). The pooled intervention effect
size was small (0.21; 95% CI 0.05 to 0.47; P ¼ 0.120).
Inﬂuence of BCTs on Pooled Intervention Effect Size
We examined whether the eight unique BCTs offered in at least
three studies explained the heterogeneity in intervention effect
sizes (see Table 3). In total, eight comparison tests were done for
analyses of the inﬂuence of BCTs on pooled intervention effect
size. We observed a statistically signiﬁcant difference in pooled
effect size between interventions that did and did not apply “cope
with side effects” and that did and did not apply “general
intention formation.” Interventions in which “cope with side
effects” was applied had a pooled SMD of 0.64 (95% CI 0.31–0.96)
versus 0.02 (95% CI 0.25 to 0.28) for those that did not (the
subgroup difference’s P ¼ 0.003; P value corrected using the
Bonferroni method was equal to 0.024). Interventions that applied
“general intention formation” had a pooled SMD of 0.15 (95% CI
0.34 to 0.04) and those that did not apply it had a pooled SMD of
0.37 (95% CI 0.05–0.69) (the subgroup difference’s P ¼ 0.006; P
value corrected using the Bonferroni method was equal to 0.048).
Sensitivity Analyses and Publication Bias
The analysis of heterogeneity showed that excluding any of the
10 included studies did not inﬂuence the heterogeneity’s value
(which ranged from I2 ¼ 79% to I2 ¼ 84%; median ¼ 83%) (see
Appendix Table S6 in Supplemental Materials found at 10.1016/j.
jval.2015.02.017). The visual examination of the funnel plot
indicated a fairly symmetrical distribution of the studies’ pooled
effect size. In addition, the nonparametric “trim and ﬁll” method
conﬁrmed the absence of publication bias (see Appendix Fig. 1 in
Supplemental Materials found at 10.1016/j.jval.2015.02.017).Discussion
When taken as recommended, OADs can control type 2 diabetes,
but many adults who require these drugs do not adhere to their
prescribed regimens. Understanding whether adherence-
enhancing interventions are effective and which components
are involved can inform future interventions and possibly clinical
practice. Fourteen trials were included in this systematic review,
of which 10 with a medium to high internal validity were
included in the meta-analysis. The pooled effect estimate of
behavior change interventions on adherence was small with
considerable heterogeneity. We explored the inﬂuence of eight
Fig. 2 – Forest plots of pooled effect size estimates for the 10 studies included in the meta-analysis. CI, conﬁdence interval; IV,
inverse variance SE, standard error.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 3 0 – 5 4 0 537unique BCTs on the pooled intervention effect size and found
that helping patients cope with side effects and formulate desired
treatment outcomes (i.e., intention formation) signiﬁcantly modi-
ﬁed the pooled effect size.
The small pooled effect size observed could be explained by a
few factors. First, the interventions added only a small number ofTable 3 – Inﬂuence of behavior change techniques on po
Behavior change techniques N
Hedges
Provide general information
Applied 5 0.34
Not applied 5 0.08
Test for subgroup differences
Self-report of behavior
Applied 3 0.54
Not applied 7 0.08
Test for subgroup differences
Reinforcement on motivational progress
Applied 3 0.15
Not applied 7 0.23
Test for subgroup differences
Plan coping responses
Applied 5 0.24
Not applied 5 0.17
Test for subgroup differences
General intention formation*
Applied 3 0.15
Not applied 7 0.37
Test for subgroup differences
Speciﬁc goal setting
Applied 4 0.15
Not applied 6 0.27
Test for subgroup differences
Continuous professional support
Applied 3 0.09
Not applied 7 0.28
Test for subgroup differences
Cope with side effects*
Applied 3 0.64
Not applied 7 0.02
Test for subgroup differences
Hedges’s g, standard mean difference; I2, indicator of heterogeneity.
* Behavior change technique signiﬁcantly inﬂuencing the pooled interveBCTs to the usual care already provided to the control groups [22].
Second, psychosocial theory was used in only one of the inter-
ventions included in our meta-analysis [37], but a literature
review suggests that more effective use of behavior change
theory may increase intervention effects [51]. Third, the level of
OAD adherence at baseline was already high in 4 of the 10 studiesoled intervention effect size.
Random-effects models
’s g 95% CI P I2
0.06 to 0.74 0.100 86%
0.29 to 0.45 0.680 80%
0.350 –
0.06 to 1.14 0.080 84%
0.20 to 0.37 0.660 81%
0.170 –
0.36 to 0.66 0.560 81%
0.08 to 0.55 0.140 83%
0.780 –
0.07 to 0.55 0.120 79%
0.33 to 0.68 0.500 87%
0.820 –
0.34 to 0.04 0.120 0%
0.05–0.69 0.020 82%
0.006 –
0.16 to 0.46 0.350 79%
0.19 to 0.74 0.250 86%
0.660 –
0.28 to 0.46 0.630 73%
0.10 to 0.65 0.150 86%
0.490 –
0.31–0.96 0.000 56%
0.25 to 0.28 0.900 75%
0.003 –
ntion effect size.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 3 0 – 5 4 0538[37–39,45], which decreased the opportunity to improve adher-
ence with an intervention [52]. Finally, the small effect observed
could be explained by poor intervention delivery [53].
The intervention components offered to intervention and
control groups varied in type and number from one study to
another. We found that interventions that introduced strategies
for patients to cope with side effects had a small pooled effect
size. “Cope with side effects” reﬂected that the intervening
physician or pharmacist had actively informed the patients about
the side effects and provided solutions for them (e.g., alternative
medications) or that the patient could quickly contact his or her
physician or pharmacist between visits in case of side effects [22].
This ﬁnding is in line with the literature that suggests that side
effects are common and also one of the most important barriers
to adherence to OAD treatment [54,55]. Hence, although it would
appear to be obvious, one recommendation for clinical practice
would be to more routinely and systematically assess side effects
and help patients overcome them.
Our results suggest that the use of “general intention for-
mation” in interventions might slightly decrease OAD adherence.
This result, however, must be interpreted with caution in light of
the exploratory nature of these analyses. Our explanation for this
counterintuitive ﬁnding is that in studies in which “general
intention formation” was part of the intervention, study partic-
ipants had higher OAD adherence at baseline. Moreover, the BCT
“cope with side effects” was applied only in those studies that did
not apply the BCT “general intention formation,” those latter
studies being the comparison group for the BCT “general inten-
tion formation.” Therefore, our observation of a decrease in
adherence when the BCT “general intention formation” is applied
might be because this BCT was indirectly compared with the BCT
“cope with side effects,” with the latter being effective at
enhancing OAD adherence.
Strengths and Limitations
This study is one of the few in the ﬁeld of medication adherence
to code the components of interventions and attempt to obtain
appropriate descriptions of the support provided to control
groups as part of usual care. Two independent coders conducted
all the coding, and we selected only quality studies for the meta-
analyses. Moreover, all studies included in our meta-analysis
were randomized controlled trials. Therefore, one could expect
some patients’ characteristics that are likely to be associated with
medication adherence (e.g., depression) would be equally dis-
tributed in the intervention and control groups. The medication
possession ratio (MPR) was used to measure adherence in two
studies [39,46]. Because the MPR can in theory be greater than
100%, including studies using the MPR could have inﬂated to
some extent the effect size in a clinically nonrelevant way.
Although the authors of one study [46] did not mention how
they handled cases of MPR greater than 100%, in the other study
[39], the MPR was capped at 100%. Moreover, in our sensitivity
analyses, excluding the effect size from those two studies had no
impact on the pooled intervention effect size estimate. Our
review also has some limitations. First, we classiﬁed SMDs as
small, medium, or large as suggested by Cohen. When interpret-
ing these SMDs, however, one should be aware that the clinical
signiﬁcance of such an effect size for patient health is unclear.
Second, the small number of studies included limited the possi-
bility of exploring the inﬂuence of individual BCTs on interven-
tion effectiveness. This is a common issue in meta-analysis [56–
58]. Third, despite our considerable efforts to obtain comprehen-
sive descriptions of the adherence support provided to the
intervention and control groups from the study authors (because
the articles tended to lack the appropriate level of detail), these
could not always be obtained. Hence, more BCTs might have beenapplied in both arms than we were able to determine. This is a
common problem that illustrates the importance of improved
intervention and control group descriptions in behavior change
intervention trials [59,60]. In addition, in the analyses that
explored the inﬂuence of individual BCTs, the pooled effect sizes
obtained from the subgroup analyses may have been confounded
by the unmeasured effects of other intervention characteristics
[61]. Finally, most of the studies were conducted in the United
States, which limits the generalizability of the ﬁndings.Implications for Clinicians and Policymakers
Our article provides evidence-based information on the impor-
tant components of adherence-enhancing interventions in adults
with type 2 diabetes. This knowledge is crucial for a wide variety
of health care professionals (physicians, pharmacists, nurses,
and health educators), patients, researchers, and policymakers
who are interested in enhancing OAD adherence. Researchers
could use the ﬁndings of this review to develop more efﬁcient
interventions to enhance OAD adherence. The ﬁndings of this
review could help health care professionals to identify effective
adherence-enhancing interventions that could be implemented
in their practice. This article could also inform policymakers’
decisions regarding the ﬁnancing, the design, the implementa-
tion, and the evaluation of adherence-enhancing intervention
programs. The ﬁndings of this review might ultimately increase
the quality of care by allowing patients to receive a better support
in the management of their disease.Conclusions
Behavior change interventions seem to have a small, favorable
effect on adherence to OAD treatment. Interventions that include
helping people cope with their side effects seem to be particularly
effective in improving adherence to OAD treatment, and we
recommend including this in OAD adherence-enhancing inter-
ventions. Future studies with better-designed and better-reported
interventions are required to identify other BCTs that could
beneﬁt patients. Researchers should also make efforts to better
capture the content of usual care at the moment behavioral
change interventions are offered.Acknowledgments
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